Separating LNP Manufacture from Cargo Incorporation: The Route to Globally Accessible and Personalised RNA Therapeutics
Time: 9:45 am
day: Day One
Details:
- Understanding the need to introduce RNA payload during LNP formation and the resulting ultra-cold chain requirements limiting the suitability of LNPs for global vaccine rollouts or for small batch production of personalized medicine
- SiSaf has developed silicon stabilized hybrid LNPs (sshLNPs) that can be produced empty and loaded with RNA cargo in a separate step
- sshLNPs can not only be stored and shipped at fridge temperature but they also offer other key advantages over conventional LNPs, such as enhanced safety, RNA stability, transfection efficiency and non-hepatic delivery
